Gastroenterologie
a hepatologie

Gastrointestinal tract involvement in hereditary kidney diseases

Miroslav Merta¹

+ Affiliation
¹ Ústav biologie a lékařské genetiky, 1. LF UK a VFN Praha

Summary

Hereditary kidney diseases are an important and specific group of kidney diseases having often systemic and multiorgan characteristics and a tendency to progress to chronic renal failure. The genetic background of the majority of hereditary nephropathies has been reported, an important step has been made to uncover their etiology and pathogenesis, and recently new innovative therapies have been proposed. Gastrointestinal tract (GIT) involvement in hereditary kidney diseases presents in different forms, extents, and intensities. Though only a minor part of hereditary kidney disease, GIT involvement is an integral component of the clinical picture; for example, liver cysts are an important component of autosomal dominant polycystic kidney disease. Even mild symptoms of GIT involvement can be an initial and potentially serious extrarenal manifestation of hereditary nephropathy, which deserves early diagnosis and initiation of treatment.

Keywords

hereditary kidney diseases, liver cysts, congenital hepatic fibrosis, renal cysts, molecular biology methods, polycystic kidney disease, gastrointestinal tract involvement

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Van Hoeve K, Mekahli D, Morava E et al. Liver involvement in kidney disease and vice versa. Pediatr Nephrol 2018; 33 (6): 957–971. doi: 10.1007/s00467-017-3715-3.
2. Hofer J, Rosales A, Fischer C et al. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr 2014; 2: 97. doi: 10.3389/fped.2014.00097.
3. Harris PC, Torres VE. Polycystic kidney disease, autosomal dominant. In: Adam MP, Ardinger HH, Pagon RA et al. (eds). GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle: 1993–2018.
4. Abu-Wasel B, Walsh C, Keough V et al. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. World J Gastroenterol 2013; 19 (35): 5775–5786. doi: 10.3748/wjg.v19.i35.5775.
5. Cnossen WR, Drenth JP. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet J Rare Dis 2014; 9: 69. doi: 10.1186/1750-1172-9-69.
6. Hogan MC, Abebe K, Torres VE et al. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol 2015; 13 (1): 155–164. doi: 10.1016/j.cgh.2014.07.051.
7. Kim H, Park HC, Ryu H et al. Clinical correlates of mass effect in autosomal dominant polycystic kidney disease. PLoS One 2015; 10 (12): e0144526. doi: 10.1371/journal.pone.0144526.
8. Chebib FT, Jung Y, Heyer CM et al. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2016; 31 (6): 952–960. doi: 10.1093/ndt/gfw008.
9. Chebib FT, Harmon A, Irazabal Mira MV et al. Outcomes and durability of hepatic reduction after combined partial hepatectomy and cyst fenestration for massive polycystic liver disease. J Am Coll Surg 2016; 223 (1): 118–126.e1. doi: 10.1016/j.jamcollsurg.2015.12.051.
10. Besse W, Dong K, Choi J et al. Isolated polycystic liver disease genes define effectors of polycystin-1 function. J Clin Invest 2017; 127 (9): 3558. doi: 10.1172/JCI96729.
11. Mikolajczyk AE, Te HS, Chapman AB. Gastrointestinal manifestations of autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol 2017; 15 (1): 17–24. doi: 10.1016/j.cgh.2016.06.017.
12. Morris-Stiff G, Coles G, Moore R et al. Abdominal wall hernia in autosomal dominant polycystic kidney disease. Br J Surg 1997; 84 (5): 615–617.
13. Wehrman A, Kriegermeier A, Wen J. Diagnosis and management of hepatobiliary complications in autosomal recessive polycystic kidney disease. Front Pediatr 2017; 5: 124. doi: 10.3389/fped.2017.00124.
14. Bergmann C. Genetics of autosomal recessive polycystic kidney disease and its differential diagnoses. Front Pediatr 2018; 5: 221. doi: 10.3389/fped.2017.00221.
15. Gunay-Aygun M, Font-Montgomery E, Lukose L et al. Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology 2013; 144 (1): 112–121. e2. doi: 10.1053/j.gastro.2012.09.056.
16. Mekahli D, van Stralen KJ, Bonthuis M et al. Kidney versus combined kidney and liver transplantation in young people with autosomal recessive polycystic kidney disease: data from the European Society for Pediatric Nephrology/European Renal Association-European Dialysis and Transplant (ESPN/ERA-EDTA) registry. Am J Kidney Dis 2016; 68 (5): 782–788. doi: 10.1053/j.ajkd.2016.06.019.
17. Hartung EA, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics 2014; 134 (3): e833–845. doi: 10.1542/peds.2013-3646.
18. Abbes K, Ayadi L, Makni S et al. Esophageal leiomyomatosis revealing an Alport syndrome. Rev Med Interne 2009; 30 (1): 88–90. doi: 10.1016/j.revmed.2008.02.025.
19. Nozu K, Minamikawa S, Yamada S et al. Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis. J Hum Genet 2017; 62 (7): 733–735. doi: 10.1038/jhg.2017.28.
20. Burgos R, Muñiz E, Rosa ER et al. Comprehensive management of diffuse leiomyomatosis in a patient with Alport syndrome. P R Health Sci J 2013; 32 (4): 200–202.
21. Staley BA, Vail EA, Thiele EA. Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs. Pediatrics 2011; 127 (1): e117–125. doi: 10.1542/peds.2010-0192.
22. Santos L, Brcic I, Unterweger G et al. Hamartomatous polyposis in tuberous sclerosis complex: Case report and review of the literature. Pathol Res Pract 2015; 211 (12): 1025–1029. doi: 10.1016/j.prp.2015.09.016.
23. Hilz MJ, Arbustini E, Dagna L et al. Non-specific gastrointestinal features: Could it be Fabry disease? Dig Liver Dis 2018; 50 (5): 429–437. doi: 10.1016/j.dld.2018.02.011.
24. Ortiz A, Germain DP, Desnick RJ et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 2018; 123 (4): 416–427. doi: 10.1016/j.ymgme.2018.02.014.
25. Bhasin B, Ürekli HM, Atta MG. Primary and secondary hyperoxaluria: Understanding the enigma. World J Nephrol 2015; 4 (2): 235–244. doi: 10.5527/wjn.v4.i2.235.
26. Bollée G, Cochat P, Daudon M. Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria. Can J Kidney Health Dis 2015; 2: 31. doi: 10.1186/s40697-015-0069-2.
27. Sakari Jokiranta T, Viklicky O, Al Shorafa S et al. Differential diagnosis of thrombotic microangiopathy in nephrology. BMC Nephrol 2017; 18 (1): 324. doi: 10.1186/s12882-017-0727-y.
28. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6: 60. doi: 10.1186/1750-1172-6-60.
29. Kim SH, Kim HY, Kim SY. Atypical hemolytic uremic syndrome and eculizumab therapy in children. Korean J Pediatr 2018; 61 (2): 37–42. doi: 10.3345/kjp.2018.61.2.37.
30. Reeders ST, Breuning MH, Davies KE et al. A highly polymorphic DNA marker linked to adult polycystic kidney disease on chromo-some 16. Nature 1985; 317 (6037): 542–544.